Meta Halogenation of 1,3-Disubstituted Arenes via Iridium-Catalyzed Arene Borylation
作者:Jaclyn M. Murphy、Xuebin Liao、John F. Hartwig
DOI:10.1021/ja076498n
日期:2007.12.1
copper(II) bromide or chloride converts arylboronic esters to the corresponding aryl halides. A variety of arenes containing alkoxy, alkyl, halogen, nitrile, ester, amide, and pivaloyl and TIPS-protected alcohols were converted to the corresponding 3,5-disubstituted aryl bromides and chlorides in yields ranging from 46% to 85%. In addition, 2,6-disubstituted and 3-substituted pyridines were converted
PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS
申请人:Chakravarty Devraj
公开号:US20120302610A1
公开(公告)日:2012-11-29
The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
Here we used 19F NMR fragment screening for the discovery of novel, ligand-efficient SPR inhibitors. We report the crystal structures of six chemically diverse inhibitors complexed with SPR, identifying relevant interactions and binding modes in the sepiapterin pocket. Exploration of our initial fragment screening hit led to double-digit nanomolar inhibitors of SPR with excellent ligand efficiency.
在慢性下背痛患者中的全基因组关联研究认为,Sepaapterin还原酶是开发新型镇痛药的重要目标。在这里,我们使用19 F NMR片段筛选来发现新型的,配体有效的SPR抑制剂。我们报告了与SPR配合使用的六种化学多样的抑制剂的晶体结构,确定了Sepaapterin口袋中的相关相互作用和结合模式。对我们最初的片段筛选命中的探索导致了具有出色配体效率的两位数纳摩尔SPR抑制剂。
Biphenyl derivatives useful as glucagon receptor antagonists
申请人:Chakravarty Devraj
公开号:US09045389B2
公开(公告)日:2015-06-02
The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
申请人:Chakravarty Devraj
公开号:US08748624B2
公开(公告)日:2014-06-10
The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.